Malin Life Sciences Holdings Ltd - 16 Nov 2021 Form 4 Insider Report for Poseida Therapeutics, Inc.

Role: Common director with Issuer, 10%+ Owner
Signature: /s/ Pat Jennings, Chief Financial Officer
Issuer symbol: N/A
Transactions as of: 16 Nov 2021
Net transactions value: +$2,731,889
Form type: 4
Filing time: 18 Nov 2021, 19:24:33 UTC
Next filing: 23 Nov 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PSTX	COMMON STOCK	Purchase	$198,383	+27,680	+0.3%	$7.17	9,215,805	16 Nov 2021	Direct	F1
transaction	PSTX	COMMON STOCK	Purchase	$2,021,821	+280,384	+3%	$7.21	9,496,189	17 Nov 2021	Direct	F1
transaction	PSTX	COMMON STOCK	Purchase	$511,685	+71,312	+0.75%	$7.18	9,567,501	18 Nov 2021	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported prices in Column 4 are weighted average prices. Those shares were purchased in multiple transactions at per share prices ranging from $7.06 to $7.25 on 11/16/2021; $6.97 to $7.37 on 11/17/2021; and $6.84 to $7.29 on 11/18/2021. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Content

The reported prices in Column 4 are weighted average prices. Those shares were purchased in multiple transactions at per share prices ranging from $7.06 to $7.25 on 11/16/2021; $6.97 to $7.37 on 11/17/2021; and $6.84 to $7.29 on 11/18/2021. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.